Trial Profile
A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Radalbuvir (Primary) ; Vedroprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms SYNERGY
- Sponsors Gilead Sciences
- 17 Apr 2016 Results assessing Sofosbuvir-based therapy among patients with mental health disease from SPARE, SYNERGY-A and ERADICATE studies, spresented at The International Liver Congress™ 2016.
- 17 Apr 2016 Results of an integrated analysis from five trials (n=236) presented at The International Liver Congress™ 2016
- 01 Jan 2016 Results of pooled analysis of 2 phase II trials (NCT01805882 and NCT01878799) published in the AIDS